Antagonist binding profiles of five cloned human muscarinic receptor subtypes by Dörje, F. et al.
0022-3565/91/2562-0727SOO.OO/O 
THE JOURNAL OP PHARNACOLOGY AND EXPERIMENTAL THERAPEUTICS 
Copyright C 1991 by The American Society Cor Pharmacolol)' and Ezperimental Therapeutica 
Vol. 256, No. 2 
Printed in U.S.A. 
Antagonist Binding Profiles of Five Cloned Human Muscarinic 
Receptor Subtypes 1 
FRANK OÖRJEI2 JÜRGEN WESSI GÜNTER LAMBRECHTI REINHOLD TACKEI ERNST MUTSCHLER and 
MARK R. BRANN3 
Laborstory of Molecu/ar Biology (F.D. 1 J.W. 1 M.R.8.}1 Nationalinstitute of Neurological Disordersand Strake, Nationalinstitutes of Health, Bethesda, 
Maryland 20892; Department of Pharmscology (F.D., G.L., E.M.), University of Frankfurt, Theodor-Stern-Kai 71 GebSude 75A, D-6000 FrankfurtfM., 
Federst Republlc of Germany; and Institute of lnorganic Chemistry (R. T.), University of Karlsruhe, EngesserstrsBe, D-7500 Karlsruhe, Federal 
Republic of Germany 
Accepted for publication November 5, 1990 
ABSTRACT 
A variety of muscarinic antagonists are currently used as tools 
to pharmacologically subclassify muscarinic receptors into M11 
M2 and M3 subtypes. ln the present study I we have determined 
the affinity proflies of several of these antagonists at five cloned 
human muscarinic receptors (m1-m5) stably expressed in 
Chinesehamster ovary cells (CHO-K1). At all five receptorsl the 
(R)-enantiomers of trihexyphenidyl and hexbutinol displayed con-
siderably higher affinities (up to 525-fold) than their correspond-
ing (S)-isomers. The stereoselectivity ratios [inhibition con-
stant(S)/inhibition constant(R)] for both pairs of enantiomers 
were lowest at m2 receptors, suggesting that less stringent 
configurational demands are made by this receptor subtype. The 
"M1-selective" antagonist (R)-trihexyphenidyl displayed high affin-
ities for m1 and m4 receptors. The "M2-selective" antagonists 
himbacinel (±}-5, 11-dihydro-11-1[(2-[(dipropylamino)methyl]-1-
piperidinyllethyl)amino]carbonyii-6H-pyrido(213-b)(1 ~4)benzodi­
azepine-6-one (AF-DX 384)1 11-(14-[4-(diethylamino)butyl)-
By the use of selective antagonists, pharmacologists have 
identified at least three muscarinic receptor subtypes, desig-
nated M11 M2 and M3• Antagonists used in this subclassification 
include pirenzepine (M1 selective), AF-DX 116, methoctramine, 
himbacine (M2 selective) and HHSiD, p-F-HHSiD, sila-hexo-
cyclium and 4-DAMP (Mt/M3 selective) (for reviews, see 
Mitchelson, 1988; Lambrecht et al., 1989a; see also table 3). 
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1-piperidinyll acetyl)-5~ 11-dihydro-6H-pyrido(2~3-b) 
(1~4)benzodiazepine-6-one (AQ-RA 741) and (+K11-(12-[(dieth-
ylamino )methyl]-1-piperidinyll acetyl)-5~ 11-di-hydro-6H-pyr-
ido(2~3-b)(1 ~4)benzodiazepine-6-one (AF-OX 250; the (+)-en-
antiomer of AF-DX 116] exhibited high affinities for m2 and m41 
intermediate affinities for m1 and m3 and low affinities for m5 
receptors. This selectivity profile was most prominent for AQ-RA 
7 41 I which displayed 195- and 129-fold higher affinities for m2 
and m4 receptors than for mS receptors. The "M3-selective" 
antagonist (±)-p-fluoro-hexahydro-sila-difenidol hydrochloride (p-
FHHsiD) exhibited high affinity for m1 I m3 and m4 receptors. 4-
diphenylacetoxy-N-methylpiperidine methiodide (4-DAMP) bound 
with up to 7 -fold higher affinities to m1 I m31 m4 and m5 receptors 
than to m2 receptors. Although none of the tested antagonists 
showed more than 2-fold selectivity for one subtype over all 
other subtypes, each receptor displayed a unique antagonist 
binding profile. 
More recently, five muscarinic receptors have been cloned (ml-
m5) (for reviews, see Hulme et al., 1990; Jones et al., in press) 
and shown to be widely expressed in the brain and in peripheral 
tissues (Peralta et al., 1987; Buckley et al., 1988; Maeda et al., 
1988; Weiner et al., 1990). While conventional pharmacologic 
sturlies on muscarinic receptor subtypes are complicated by the 
fact that most tissues express a mixture of different muscarinic 
receptor genes (Buckley et al. 1988; Maeda et al., 1988; Weiner 
et al., 1990), the use of transformed cell lines individually 
expressing the various receptors offers the advantage that 
distinct subtypes can be studied in isolation. To date, only a 
limited characterization of the antagonist binding properties of 
the m1 to m5 receptors has been performed (Bonner et al., 
1987, 1988; Peralts et al., 1987; Akiba et al., 1988; Buckley et 
al., 1989). In these studies, the antagonist binding properties of 
ABBREVIATIONS: HHSiD, (±)-hexahydro-sila-difenidol hydrochloride; [3H]NMS, [3H]N-methylscopolarnine chloride; 4-DAMP, 4-diphenylacetoxy-N-
methyfpiperidine methiodide; p-F-HHSiD, {±)-p-fluoro-hexahydro-sila-difenidol hydrochloride; AF-DX 250, ( + )-[11-( 12-[(diethylamino)methyl)-1-piperi-
dinyllacetyl)-5, 11-dihydro-6H-pyrido(2,3-bX1 ,4 )benzodiazepine-6-one: AO-RA 7 41 , 11-( 14-[ 4-(diethylamino)butyl]-1-piperidinyll acetyl)-5, 11-dihydro-
6H-pyrido(2,3-bX1 ,4)benzodiazepine-6-one: AF-DX 384, (±)-5, 11-dihydro-11-1[(2-12-[(dipropylamino)methyl)-1-piperidinyllethyl)amino]carbonyii-6H-
pyrido{2,3-bX1 ,4)benzodiazepine-6-one; K" inhibition constant. 
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the m2 and m3 receptors correlated weil with those of the 
pharmacologically defined M2 and M3 subtypes (Peralta et al., 
1987; Akiba et al., 1988; Buckley et al., 1989). However, the 
antagonist binding properties of both m 1 and m4 receptors 
were similar to those of Mt receptors, suggesting that the 
putative Mt receptors may be composed of a mixture of these 
two receptor proteins (Buckley et al., 1989). 
Many of the antagonists commonly used to classify musca-
rinic receptor subtypes have not been studied at cloned recep-
tors. To ensure a judicious use of these compounds as phar-
macologic tools for receptor subclassification and to further 
characterize the antagonist binding properties of the m1 to m5 
receptors, we have determined the affinities of 11 muscarinic 
antagonists (fig. 1) for the five cloned human muscarinic recep-
tors stably expressed in CHO-K1 cells. The enantiomers of 
trihexyphenidyl and hexbutinol were tested to study the ster-
eochemical demands of the individual subtypes. These stereo-
isomer& have been used as tools to classify Mt to M3 muscarinic 
receptor subtypes (Lambrecht et al., 1988b, 1989a; Feifel et al., 
1990). Furthermore, we have investigated two widely used 
"selective" antagonists, 4-DAMP (Barlow et al., 1976; Doods et 
al., 1987) and p-F-HHSiD (Lambrecht et al., 1988a, 1989a,b), 
as weil as a series of "M2-selective" antagonists including 
methoctramine (Melchiorre et al., 1987; Waelbroeck et al., 
1989a), himbacine (Gilani and Cobbin 1986; Lazareno and 
Roberts 1989), AF-DX 384, AQ-RA 741 and AF-DX 250 [(+)-
Q OH C5c~ 0 CH2-CH2-N Trlhexyphenldyl 
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enantiomer of AF-DX 116] (Eberlein et al., 1989; Engelet al., 
1989) (for chemical structures, see fig. 1). AF-DX 384 and AQ-
RA 741 are new derivatives of the well-known antimuscarinic 
drug AF-DX 116 and have been found tobemorepotent and/ 
or selective than the parent compound (Eberlein et al., 1989). 
Materials and Methods 
Cell culture. Chinesehamster ovary cells (CHO-K1) were obtained 
from the American Type Culture Collection. Except for the ovemight 
transfection procedure, cells were incubated at 37•c in a humidified 
atmosphere (5% C02) as a monolayer culture in Dulbecco's modified 
Eagle's medium supplemented with 10% fetal calf serum (Gibco, Grand 
Island, NY), 100 units/ml each of penicillin G and streptomycin, and 
4 mM glutamine (M.A. Bioproducts, Walkersville, MD). 
Transfeetion procedure. Tbe CHO-K1 celllines stably expressing 
the human m2 to m5 receptors have been described previously (Buckley 
et al., 1989). To establish a cellline expressing the human m1 receptor, 
CHO-K1 cells were transformed with a plasmid containing the human 
m1 coding sequence (Bonner et al., 1988) inserted into the pcD expres-
sion vector (Okayama and Berg, 1983). Cella were transfected according 
to the method of Chen and Okayama (1987) using a modified calcium 
phosphate procedure involving the use of cotransfected pcDneo as a 
selectable marker. Selection with the neomycin analog G 418 (600 pg/ 
ml; Gibco, NY) was started 72 h after transfection and continued for 2 
to 3 weeks. Media were changed every 3 days. Clonal cell lines were 
obtained by single-cell cloning and assayed for [3H)NMS binding 
capacity. 
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Flg. 1. Chemical structures of muscarinic antagonists employed in this study. •Centers of chirality. 
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Flg. 2. Saturation isotherms of specific [3H)NMS binding to five human muscarinic receptor subtypes (m1-m5) stably expressed in CHO-K1 cells. 
Data are shown as mean values taken from a representative experiment carried out in duplicate and are typical of three to six independent 
experiments. 
TABLE 1 
Equllibrium dlssoclation constants, Hili coefficienta and total 
number of muscarinic blndin" altes (Bmu) in stably transfonned 
CHO-K1 cells, derived from [ H]NMS saturation experiments 
The data generatedas described under "Materials and Methods" represent the 
mean ± S.E.M. of at least three independent experiments, each run in duplicate. 
Hili numbers were not significantly different from unity (P > .05; unpaired, one-
talled Student's t test). 
m1 
m2 
m3 
m4 
m5 
P" 
54± 1 
83±4 
52 ±2 
26±5 
106±11 
0.96 ± 0.06 
0.94 ± 0.06 
0.94 ± 0.11 
0.95 ± 0.05 
0.94 ± 0.11 
• Ko. dissociation constant; nH, Hili coefficlent. 
tmolfmg pre1ein 
2518 ± 125 
747 ± 21 
1830 ± 40 
1778 ± 182 
954 ± 90 
Membrane preparation. Cells were grown to about 80% conflu-
ence, washed, scraped into ice-cold binding buffer and homogenized for 
30 sec using a Brinkmann Homogenizer (setting 5). Membranes were 
pelleted at 16,000 X g for 15 min and rehomogenized. Protein concen-
trations were determined according to the method of Bradford (1976) 
using a Bio-Rad protein assay kit. Membranes were stored frozen at 
-so·c before use. 
Radioligand binding studies. Binding buffer consisted of 25 mM 
sodium phosphate (pH 7.4) containing 5 mM magnesium chloride. 
Assays were conducted in 1 ml total volume. Final membrane protein 
concentrations (in #'g/ml) were: m1, 6; m2, 10; m3, 5; m4, 3; and m5, 4. 
In [3H]NMS saturation experiments, 8 to 10 different concentrations 
of the radioligand (2-1400 pM) were employed. For displacement ex-
periments, the concentration of [3H)NMS was 150 pM and 10 different 
concentrations of the cold displacers were used. Specific binding was 
defined as the difference in [3H)NMS binding in the absence and 
presence of 1 #'M atropine. Incubations were carried out at 22·c for 3 
h. Assays were terminated by filtration through a Brandeil cell har-
vester onto Whatman GF/C filters. Membranes were washed three 
times with 5 ml of ice-cold binding buffer before being dried, transferred 
to 10 ml of scintillant (New England Nuclear Aquasol) and counted in 
an LKB ß-counter. 
Data analysi&. Data from direct binding experiments were fitted 
to the equation: 
a = (ßiiiU r'/k)/(1 + Y!'/k) 
to derive the Hili coefficient n and to: 
a = (BIDU x/Ko)/(1 + x/Ko) 
to obtain the dissociation constant K0 and the total number of binding 
sites Bmu (a = (3H]NMS specifically bound; x = (3H]NMS concentra-
tion). Data from displacement experiments were fitted to the equation: 
% [3H)NMS bound = 100- [100.t"/k/(l + x"/k)] 
to obtain the Hili number n and to: 
% [3H]NMS bound = 100- [100x/1Coo/0 + x/IC60)] 
to derive the IC50 value (x = concentration of the cold inhibitor). Ki 
values were calculated by the method of Cheng and Prusoff (1973): 
Kj = IC50/(l + L/Ko) 
where L is the concentration of the radioligand, IC50 is the concentra-
tion of drug causing 50% inhibition of the specific radioligand binding 
and Ko the dissociation constant of the radioligand receptor complex. 
Data were analyzed by a nonlinear Ieast-squares curve fitting procedure 
using the program DATAPLOT (distributed by the National Technical 
Information Services) run on a VAX II computer. 
Stati&tical evaluation. Results are expressed as mean values ± 
S.E.M. of n experiments. Statistical significance was assessed using 
Student's t test or Scheffe's method (Wallenstein et al., 1980); P < .05 
was accepted as being significant. 
Drugs. Drugs were obtained from the following sources: (3H)NMS 
(71 Ci/mmol; New England Nuclear, Boston, MA); atropine sulfate, 4-
DAMP and methoctramine tetrahydrochloride (Research Biochemi-
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TABLE 2 
Binding peremeten of mu.cerlnlc ent.gonlata et flve humen mu.cerlnlc receptor aubtypea 
The afftnlty estlmates were derived from ('HJNMS displacament experiments and represent the mean (±S.E.M.; n • 3-5) for the negative logartthm of the K •. The Hil 
coefflcients are given in parentheses. HIU numbers shown are not signlficantty different from unity (P > .05; unpalred, one-talled Student's t test). 
Antagonist m1 m2 
(R)-Trihexyphenidyl 9.43 ± 0.07 8.15 ± 0.04 
(0.97 ± 0.02) (0.90 ± 0.05) 
(S)-Trthexyphenldyt 6.91 ± 0.05 6.31 ± 0.15 
(1.02 :t 0.05) (1 .00 ± 0.07) 
(R)-Hexbutlnol 8.68 ± 0.02 7.68 ± 0.04 
(1.02 ± 0.10) (0.92 ± 0.09) 
(S)-Hexbutlnol 7.58 ± 0.03 7.14 ± 0.05 
(1.08 ± 0.07) (1.06 ± 0.05) 
Pirenzepine- 8.20 ± 0.13 6.65 ± 0.05 
(0.94 ± 0.07) (1 .00 ± 0.04) 
p-F-HHSiD 7.65 ± 0.03 6.88 ± 0.04 
(1.00 ± 0.02) (1.00 ± 0.00) 
4-0AMP 9.24 :t 0.06 8.42 ± 0.07 
(1.00 ± 0.03) (0.93 ± 0.05) 
Methoctramine 7.3 ± 0.11 7.88 ± 0.09 
(1.05 ± 0.02) (1.02 ± 0.08) 
Himbaclne 6.97 :t 0.08 8.00 ± 0.05 
(0.99 ± 0.08) (0.97 ± 0.1 3) 
AF-OX 384 7.51 ± 0.08 8.22 ± 0.04 
(0.92 ± 0.06) (0.95 ± 0.07) 
AO-RA 741 7.54 ± 0.03 8.37 ± 0.04 
(1 .07 ± 0.07) (1.02 ± 0.08) 
AF-DX 250 6.37 ± 0.02 7.26 ± 0.03 
(1.01 ± 0.05) (0.93 ± 0.06) 
• Data taken from Wess et a/., 1991. 
cals, Natick, MA); (R)- and (S)-trihexyphenidyl hydrochloride (enan-
tiomeric purity >99.9%; Schjelderup et al., 1987; Lambrecht et al., 
1988b) (Dr. A. J. Aasen, Oslo, Norway); himbacine hydrochloride (Dr. 
W. C. Taylor, Sydney, Australia); AF-DX 250 (enantiomeric purity 
>98.9%; Engel et al., 1989), AQ·RA 741 and AF-DX 384 (Dr. Karl 
Tbomae GmbH, Biberach an der Riss, Federal Republic of Germany); 
p-F-HHSiD and (R)- and (S)-hexbutinol (enantiomeric purity >99.8%; 
Tacke et aL, 1989) were synthesized in our laboratories (p-F-HHSiD 
was prepared by analogy to the syntbesis of HHSiD, Tacke et al., 1985). 
Results 
( 8 H)NMS saturation experiments. In all saturation ex-
periments, the musearlnie antagonist [3H]NMS showed bind-
ing isotherme eharaeterized by Hili numbers not signifieantly 
different from unity (fig. 2, table 1). The obtained dissociation 
eonstant values (table 1) ranged from 26 pM for m4 to 106 pM 
for m5 reeeptors. The [3H]NMS affinity for the human m1 
receptor was similar to that found for the rat m1 reeeptor 
(Buekley et al., 1989). Whereas the dissociation eonstant values 
determined at m3, m4 and m5 receptors elosely resembled those 
previously reported, we observed a (3H]NMS affmity for m2 
receptors which was 5-fold higher than deseribed by Buekley 
et al. (1989). 
( 8H]NMS clisplacement experimenta. The binding pa-
rameters of the tested musearinic antagonists are given in table 
2. Unlike in previous studies (Peralta et al., 1987; Buekley et 
al., 1989), all eompounds displaced (3H]NMS binding to all five 
human musearlnie receptors (m1-m5) with simple mass action 
isotherme (shown for (R)- and (8)-trihexyphenidyl and AQ-RA 
741 in fig. 3). None of the Hili eoeffieients was signifieantly 
different from unity (table 2), entirely eonsistent with the 
presence of a single population of musearlnie binding sites in 
each cellline. At all five receptor subtypes, the (R)-enantiomers 
of trihexyphenidyl and hexbutinol displayed eonsiderably 
higher affinities than the corresponding (S)-eonfigurated iso-
m3 m4 m5 
8.61 ± 0.05 9.08 ± 0.04 8.30 ± 0.05 
(0.90 ± 0.13) (0.94 ± 0.11) (0.97 ± 0.06) 
5.89 ± 0.02 6.57 ± 0.08 6.17 ± 0.07 
(1.03 ± 0.05) (0.91 ± 0.08) (0.96 :t 0.04) 
8.67 ± 0.06 8.52 ± 0.09 8.26 ± 0.06 
(1.04 ± 0.13) (1 .05 ± 0.04) (0.97 ± 0.07) 
7.34 ± 0.05 7.71 ± 0.06 7.12 :t 0.07 
(1 .08 ± 0.04) (1.00 ± 0.04) (1 .02 ± 0.03) 
6.86 ± 0.06 7.43 ± 0.05 7.05 ± 0.04 
(1.02 ± 0.05) (0.99 ± 0.07) (0.92 ± 0.08) 
7.81 ± 0.02 7.50 ± 0.01 7.03 ± 0.04 
(1.04 ± 0.02) (0.94 ± 0.03) (0.97 ± 0.09) 
9.28 ± 0.02 8.93 ± 0.10 8.98 ± 0.00 
(0.97 ± 0.08) (0.95 ± 0.03) (1 .05 ± 0.03) 
6.67 ± 0.09 7.50 ± 0.04 6.87 ± 0.07 
(0.95 ± 0.06) (1.01 ± 0.04) (1.07 ± 0.05) 
7.03 ± 0.03 7.96 ± 0.05 6.31 ± 0.05 
(0.98 ± 0.05) (0.94 ± 0.04) (1.06 ± 0.09) 
7.18 ± 0.07 8.00 ± 0.08 6.27 ± 0.04 
(0.97 ± 0.04) (0.99 ± 0.04) (0.94 ± 0.06) 
7.20 ± 0.04 8.19 ± 0.00 6.08 ± 0.05 
(1.04 ± 0.08) (1 .03 ± 0.05) (0.94 ± 0.06) 
6.16 ± 0.02 6.79 ± 0.04 5.52 ± 0.02 
(0.99 ± 0.02) (0.99 ± 0.05) (1.02 ± 0.04) 
mers (table 2, fig. 4). The stereoselectivity ratios (Ki(S)/Ki(R)] 
for the enantiomers of trihexyphenidyl and hexbutinol ranged 
from 69 (m2) to 525 (m3) and from 5 (m2) to 21 (m3), respec-
tively (fig. 4). The "M1-seleetive" antagonist (R)-trihexyphen-
idyl (Lambrecht et al., 1988b, Waelbroeck et al., 1989b) exhib-
ited high affinity to both ml and m4 receptors. (R)-Hexbutinol 
displayed the samequalitative affinity profile as p-F-HHSiD. 
The "M3·selective" agent p-F-HHSiD (IJ&mbrecht et al., 
1988a, 1989a,b) showed similar affinities for m1, m3 and m4 
receptors, whieh were up to 9-fold higher (P < .05) than those 
found for m2 and m5 receptors. The "selective" antagonist 4-
DAMP displayed similar high affinities for m1, m3, m4 and m5 
receptors, whereas its affinity for m2 receptors was at least 3-
fold lower (P < .05) than for the other subtypes. All five "M2-
selective" musearinie antagonists employed (methoctramine, 
himbaeine, AF-DX 384, AQ-RA 741 and AF-DX 250) bound 
with high affinities to both m2 and m4 receptors, with inter-
mediate affinities to m1 and m3 receptors, and, with the exeep-
tion of methoctramine, with even lower affinities to m5 recep-
tors (table 2). This feature was most prominent for AQ-RA 
741, whieh diseriminated between m2 vs. m5 and m4 vs. m5 
reeeptors by factors of 195 and 129 (P < .05), respectively. 
Diseuseion 
The eharacterization of muscarinie receptor subtypes has 
been complieated by the presenee of multiple muscarinie bind-
ing sites in most tissues. To overcome this diffieulty, the affinity 
profiles of a series of selective musearlnie antagonists has been 
studied by the use of CHO-K1 eell lines stably transformed 
with the five human musearlnie receptor genes (ml-m5). 
It has been suggested that musearlnie receptor subtypes ean 
be eharacterized based on their stereoselective interaction with 
ehiral antagonists (Lambrecht et al., 1988b, 1989a; Eltze and 
Figala, 1988; Eveleigh et al., 1989; Feifel et al., 1990). In agree-
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Fig. 3. Binding isotherms of (R)- and (S)-trihexyphenidyl and AQ-RA 7 41 
for the displacement of specific (3H)NMS binding to m1 (0), m2 ~. m3 
(6), m4 (A) and m5 (t) muscarinic receptors. The [3H)NMS concentration 
used was 150 pM. Specific bindingwas determined asthat displaced by 
1 ILM atropine. Curves are representative of at least three independent 
experiments carried out in duplicate. 
ment with these reports, the (R)-enantiomers of trihexypheni-
dyl and hexbutinol displayed considerably higher (up to 525-
fold) affinities to all five subtypes than their corresponding (8)-
enantiomers. 8tereoselectivity ratios [(Ki(8)/Ki(R)] were low-
est at m2 receptors (fig. 4), suggesting that less stringent 
configurational demands are made by this subtype. 8tereose-
lectivity ratios found for ml, m3, m4 and m5 receptors differed 
by a factor of less than 4, thus limiting the utility of the 
employed Stereoisomers to subclassify muscarinic receptors. 
The "M1-selective" antagonist (R)-trihexyphenidyl (Lambrecht 
et al., 1988b; Waelbroeck et al., 1989b), similar to its corre-
sponding (8)-enantiomer, (8)-hexbutinol and pirenzepine 
(Wess et al., 1991) displayed higher affinities for m1 and m4 
than for m2, m3 and m5 receptors. 
The "M3-selective" antagonist p-F-HH8iD (Lambrecht et al., 
1988a, 1989a,b) bound with high affinities to m1, m3 and m4 
receptors. Its binding profilewas very similar tothat obtained 
for (R)-hexbutinol and HH8iD (Buckley et al., 1989). Although 
p-F-HH8iD did not show a marked selectivity for a single 
Antagonist Binding to Mu~earinic Receptors 731 
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Fig. 4. Affinity profilas (pl<; = -log inhibition constant) of the enantiomers 
of trihexyphenidyl and hexbutinol at five human muscarinic receptor 
subtypes. The stereoselectivity ratios (K~S)/K~R)) are given on top of 
each column. 
TABLE 3 
Comparison of affinity profilas of mu~earinic receptor antagonists 
determined at pharmacologically (M,-M,) and molecularly (m1-m5) 
characterized musearlnie receptor subtypes• 
Antagonist 
(R)-Trihexyphenidyf 
(S)-Trihexyphenidyf 
(R)-Hexbutino~ 
(S)-Hexbutino~ 
Pirenzepine• 
p-F-HHSio-
4-0AMP' 
Methoctramine" 
Himbacine' 
AF-OX 384h 
AQ-RA 741h 
AF-OX 250' 
Mt >M3> M2 
Mt> M2 2: M3 
Mt= M3 > M2 
M3 2: M2 2: M1 
Mt> M3 2: M2 
M3 >Mt> M2 
M1 2: M3 > M2 
M2>Mt > M3 
Mt~ M2> M3 
M2>M3 
M2>M3 
M2 ~Mt> Ma 
Affrlity Profiles" 
m 1 ~ m4 > m3 2: m5 2= m2 
m1 ~ m4 2: m2 2: m5 2= m3 
m 1 = m3 ~ m4 2: m5 2= m2 
m4 ~ m1 2: m3 2: m2 :::: m5 
m1 > m4 ~ m5 2: m3 2= m2 
m3 2: m1 2: m4 > m5 2= m2 
m3 :::::: m1 ~ m5 :::::: m4 > m2 
m2 ~ m4 ~ m1 2: m5 2= m3 
m2 :::::: m4 > m3 :::::: m1 > m5 
m2 2: m4 > m1 2: m3 > m5 
m2 ~ m4 > m1 2: m3 > m5 
m2 ~ m4 ~ m1 2: m3 > m5 
• Affinity profiles at pharmacologically defined subtypes were determined in 
functional studies on rabbit vas deferens (M,), guinea pig atria (M2 ) and guinea pig 
longitudinal smooth muscle of the ileum (M3). ln case of AF-DX 384 and AO-RA 
7 41, data from functional studies on M, receptors were not available. 
" Differences in antagonist affinities for cloned muscarinic receptors by a factor 
of 2:3 are indicated by > and proved to be significant (P < .05). 
c.uJli.Jo Affinity proflies for M,, M2 and M3 muscarinic receptors according to 
references: c Lambrecht et BI .• 1988b; 11 Feitelet a/ .• 1990; • Lambrecht er al. , 1988a; 
'Dörje et al .• 1990 [it should be noted that himbacine shows about 10-fok:t higher 
affinity for M, receptors in the rabbit vas deferens than for rat cortical M, receptors 
(Lazareno and Roberts. 1989)]; 11 Lambrecht et al., 1989b; "Eber1ein er BI., 1989. 
subtype as previously reported (Lambrecht et al., 1988, 1989a,b; 
Eglen et al., 1990), it displayed up to 9-fold lower affinities for 
m2 and m5 than for ml, m3 and m4 receptors. 
The "selective" muscarinic antagonist 4-DAMP (Barlow et 
al., 1976; Doods et al., 1987) is widely used in both functional 
and radioligand binding studies to discriminate between M1 
and Maus. M2 receptors. In our study, this compound exhibited 
similar high affinities for m1, m3, m4 and m5 but up to 7-fold 
lower affinity for m2 receptors. This binding profile is shared 
by the pirenzepine derivative UH-AH 37 (Wess et al., 1991) 
and sila-hexocyclium (Buckley et al., 1989). 
Methoctramine (Melchiorre et al., 1987; Waelbroeck et al., 
1989a), himbacine (Gilani and Cobbin, 1986; Lazareno and 
Roberts, 1989), AF-DX 250 [the (+)-enantimer of AF-DX 116; 
Engelet al., 1989], AF-DX 384 and AQ-RA 741 (Eberlein et al., 
1989) are classified as "M2-selective" antagonists. We found, 
however, that all five antagonists possess similarly high affin-
ities to both m2 and m4 receptors (table 2). Nevertheless, 
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methoctramine, himbacine and the derivatives of AF-DX 116 
represent valuable tools to distinguish between m2 and m4 
receptors us. all other subtypes. For example, all five com-
pounds clearly discriminate between m2 ( m4) and m3 receptors 
with affinity differences ranging from 9-(himbacine) to 16-fold 
(methoctramine). With the exception of himbacine, which 
showed about a 10-fold higher affinity for m2 (m4) than for m1 
receptors, the ability of these compounds to distinguish between 
m2 (m4) receptors and m1 receptors was less pronounced. Most 
remarkably, himbacine, AF-DX 384, AQ-RA 741 and AF-DX 
250 bound to m5 receptors with substantially reduced affinities 
compared with all other subtypes (table 2). AQ-RA 741, for 
instance, displayed 195- and 129-fold lower affinities for m5 
than for m2 and m4 receptors, respectively. The close similarity 
between the selectivity proflies of himbacine and the three AF-
DX 116 derivatives is reflected in the chemical structures of 
these agents. All four antagonists are composed of a tricyclic 
ring system linked to a substituted piperidine ring by a short 
side chain (fig. 1). 
Our data indicate that musearlnie antagonists can be grouped 
based on their receptor-selectivity profiles. The most striking 
examples are the group of antagonists displaying high affinities 
for m 1 and m4 receptors, and the group of compounds exhib-
iting preferential binding for m2 and m4 receptors (tables 2 
and 3). One might speculate that the differential binding selec-
tivities of each group of antagonists are dependent on distinct 
receptor domains. For instance, residues that are identical 
between the m1 and m4 receptors may be important in the 
binding of m1/m4 selective compounds, whereas regions con-
served among m2 and m4 receptors may be essential in the 
binding of m2/m4 selective antagonists. Sequence analysis of 
the receptors provides numerous candidate regions. To deter-
mine the potential importance of these domsins for subtype-
selective antagonist binding, we are presently preparing chi-
meric muscarinic receptors. lt is hoped that these studies will 
allow a precise definition of the multiple structural determi-
nants that apparently contribute to subtype-selective drug in-
teraction. 
Although none of the tested antagonists showed a marked 
selectivity for one subtype over all other subtypes, distinct 
selectivity proflies are apparent. In general, these proflies are 
consistent with the known selectivities of antagonists for mus-
carinic receptors that led to the Mt!M2/Ma classification (table 
3). However, the present data also highlight the limitations of 
this pharmacologic scheme, demonstrating the necessity to 
determine antagonist affinities to all five muscarinic receptor 
subtypes. Whereas the antagonist affinities determined for 
cloned m2 and m3 receptors (this study) generally correlated 
well with those for the pharmacologically defined M2 and Ma 
subtypes, the assignment of the M. receptor is more problem-
atic. The antagonist binding properties of both m1 and m4 
receptor proteins were similar to those of the putative M. 
receptors. Thus, the identification of muscarinic receptors with 
M1-like antagonist binding properties in a given tissue may be 
indicative of either m1 or m4 or a mixture ofthese two receptor 
subtypes. 
Whereas most antagonists bound to m 1 and m4 receptors 
with similar affinities, two compounds, pirenzepine and him-
bacine, are able to discriminate between these two subtypes. 
Pirenzepine showed 6-fold higher affinity for m1 than for m4 
receptors (Wess et al., 1991), whereas himbacine exhibited 10-
fold selectivity for m4 receptors. Given the relatively low selec-
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tivity of pirenzepine, himbacine appears tobe the most valuable 
tool to distinguish between m1 and m4 receptors. 
The fact that the antagonists currently used to classify 
muscarinic receptors Iack a clear subtype-selectivity may ex-
plain that only three major subtypes (putative M1-M3) have 
been identified in classic pharmacologic studies. In this study, 
we have shown that all five muscarinic receptors exhibit unique 
antagonist binding profiles. Therefore, the judicious use of a 
variety of selected antagonists should eventually allow the 
pharmacologic identification of all five muscarinic receptor 
subtypes. 
In conclusion, our study has further substantiated the utility 
of cloned receptors stably expressed in mammalian celllines to 
unambiguously determine the selectivity profile of muscarinic 
antagonists. Given the considerable therapeutic potential of 
subtype-selective antimuscarinic agents (W ess et al., 1990), this 
approach should be extremely useful for the future development 
of novel antimuscarinic drugs. 
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